Derepression of HMGA2 Gene Expression in Retinoblastoma is Associated with Cell Proliferation
Overview
Molecular Biology
Authors
Affiliations
To assess whether retinoblastoma formation is associated with the expression of high mobility group (HMG) A2 protein, a transcription factor that is highly expressed during embryogenesis and completely repressed in normal adult tissues, we performed Northern and Western blots and RT-PCR analyses, and immunohistochemistry to test for HMGA2 expression. We used established retinoblastoma cell lines in tumors grown in nude mice and clinical retinoblastoma specimens, and contrasted these tumors with normal embryonic and adult retina. Adenoviral-mediated antisense experiments were conducted on the retinoblastoma cell lines to suppress HMGA2 expression and determine if cell proliferation is HMGA2-dependent. We also transfected a retinoblastoma cell line to identify cis-regulatory elements and transcription initiation sites on the HMGA2 gene promoter. HMGA2 gene expression was silenced in terminally differentiated retina of 6-wk-old mice, but it was detected in retina of a 13.5-d postcoitum embryo. Reactivation of HMGA2 gene expression was observed in the retinoblastoma cell lines Y79, WERI-Rb1, and TOTL-1, in tumors derived from some of these cells propagated in nude mice, and in a high frequency of retinoblastomas excised from human patients. This suggests that expression of HMGA2 gene in retinoblastoma cells involves a derepression process. By using an antisense approach to block HMGA2 expression, we observed a decrease in the number of proliferating retinoblastoma cells. As a 1st step toward understanding HMGA2 gene reactivation in retinoblastoma, we mapped the 2 transcription initiation sites and associated positive regulatory elements within the WERI-Rb1 cells. Our discovery of derepression of HMGA2 gene expression in retinoblastoma provides the 1st evidence that this protein might contribute to neoplastic transformation of retina cells.
Characterization of HMGA2 variants expands the spectrum of Silver-Russell syndrome.
Maharaj A, Cottrell E, Thanasupawat T, Joustra S, Triggs-Raine B, Fujimoto M JCI Insight. 2024; 9(6).
PMID: 38516887 PMC: 11063932. DOI: 10.1172/jci.insight.169425.
Genome maintenance in retinoblastoma: Implications for therapeutic vulnerabilities.
Lee C, Kim J Oncol Lett. 2022; 23(6):192.
PMID: 35527780 PMC: 9073582. DOI: 10.3892/ol.2022.13312.
Mao Y, Sun Y, Wu Z, Zheng J, Zhang J, Zeng J Cell Death Dis. 2021; 12(12):1141.
PMID: 34887387 PMC: 8660841. DOI: 10.1038/s41419-021-04431-y.
Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications.
Lee C, Kim J J Cell Physiol. 2020; 236(4):2318-2332.
PMID: 32840881 PMC: 7891620. DOI: 10.1002/jcp.30022.
Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets.
Huang B, Yang J, Cheng Q, Xu P, Wang J, Zhang Z Front Physiol. 2018; 9:776.
PMID: 29997523 PMC: 6028738. DOI: 10.3389/fphys.2018.00776.